The Indian Pharmacopoeia Commission (IPC) has sounded a cautionary note in the realm of drug safety, urging both healthcare practitioners and patients to be vigilant about potential adverse reactions linked to the painkiller Meftal. This commonly prescribed medication is widely utilized to alleviate menstrual cramps and manage rheumatoid arthritis.
Unraveling the Meftal Phenomenon
Delving into the specifics, Meftal, powered by mefenamic acid, finds its application in treating an array of conditions such as rheumatoid arthritis, osteoarthritis, dysmenorrhoea, mild to moderate pain, inflammation, fever, and dental pain.
A Closer Look at the Alert
The IPC’s drug safety alert, released on November 30, has drawn attention to a preliminary analysis conducted on adverse drug reactions gleaned from the Pharmacovigilance Programme of India (PvPI) database. The revelations unveiled a concerning association with drug reactions, particularly the emergence of eosinophilia and systemic symptoms (DRESS) syndrome.
Vigilance and Reporting: A Call to Action
In response to these findings, the alert emphasizes the crucial need for healthcare professionals, as well as patients and consumers, to actively monitor the potential occurrence of the aforementioned adverse drug reactions (ADRs) linked with the usage of Meftal.
“If such reactions are encountered,” the alert advises, “individuals should promptly report the matter to the national coordination centre of the PvPI under the commission.” This can be facilitated by submitting a form on the website www.ipc.gov.in or through the dedicated Android mobile app ADR PvPI. Alternatively, individuals can reach out to the PvPI Helpline at 1800-180-3024.
The IPC: Guardian of Drug Standards
Functioning as an autonomous institution under the Ministry of Health, the IPC assumes the critical role of establishing standards for all drugs manufactured, sold, and consumed in India. This proactive approach underscores the commitment to ensuring the safety and well-being of the populace in the realm of pharmaceuticals.
